Your browser doesn't support javascript.
loading
Self-reported and verified compliance in a phase 3 clinical trial of a novel low-dose contraceptive patch and pill.
Kaunitz, Andrew M; Portman, David; Westhoff, Carolyn L; Archer, David F; Mishell, Daniel R; Foegh, Marie.
Afiliação
  • Kaunitz AM; Department of Obstetrics and Gynecology, University of Florida College of Medicine, Jacksonville, 653-1 West 8th Street, Jacksonville, FL 32209, USA. Electronic address: andrew.kaunitz@jax.ufl.edu.
  • Portman D; Columbus Center for Women's Health Research, 99 Brice Road North, Columbus, OH 43213, USA.
  • Westhoff CL; Mailman School of Public Health, Columbia University, 722 West 168th Street, New York, NY 10032, USA.
  • Archer DF; Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, 601 Colley Avenue, Norfolk, VA 23507, USA.
  • Mishell DR; Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, 2020 Zonal Avenue, Room 220, Los Angeles, CA 90033, USA.
  • Foegh M; Department of Pharmacology, New York Medical College, Basic Science Building, 15 Dana Road, Valhalla, NY 10595, USA.
Contraception ; 91(3): 204-10, 2015 Mar.
Article em En | MEDLINE | ID: mdl-25582984
ABSTRACT

OBJECTIVE:

Pregnancy rates in US contraceptive clinical trials are increasing due to decreased treatment compliance. This study compared compliance with a new low-dose levonorgestrel (LNG) and ethinyl estradiol (EE) contraceptive patch (CP, Twirla™) with that of a low-dose combination oral contraceptive (COC) in a demographically diverse population. STUDY

DESIGN:

This analysis was part of an open-label, parallel-group, multicenter phase 3 study that randomized healthy sexually active women (17-40years) to 13cycles of LNG/EE CP or 6cycles of COC, then 7cycles of LNG/EE CP. We defined self-reported compliance as cycles that, according to diaries, show 21days of patch wear without missed days or any patch worn >7days or 21days of pill-taking without missed pill days. We verified compliance by detectable plasma presence of LNG and EE at cycles 2, 6, and 13.

RESULTS:

Of the intention-to-treat population with diary information (N=1328, mean age 26.4years, 46% minorities, 33% obese), 10.0% of the CP (n=998) versus 21.2% of the COC group (n=330) self-reported noncompliance after 6cycles (p<.001). Laboratory assessments verified 10-14% of participants in both groups as noncompliant. Self-reported perfect use did not vary between obese [body mass index (BMI) ≥30kg/m(2)] versus nonobese (BMI <30kg/m(2)) participants in both groups or when stratified by age, education, or race/ethnicity in the CP group.

CONCLUSIONS:

Self-reported compliance was significantly greater in the CP than COC group and did not vary by obesity status. Discrepancies between self-reported and verified compliance question reliability of patient diaries. IMPLICATIONS STATEMENT This paper, based on an analysis of a phase 3 trial, shows that compliance was significantly greater with a new weekly transdermal CP than with a once-daily COC in obese as well as nonobese participants. Discrepancies between self-reported compliance and laboratory-verified compliance raise questions regarding the reliability of patient diaries.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Cooperação do Paciente / Levanogestrel / Anticoncepcionais Orais Combinados / Etinilestradiol / Adesivo Transdérmico / Autorrelato Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans Idioma: En Revista: Contraception Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Cooperação do Paciente / Levanogestrel / Anticoncepcionais Orais Combinados / Etinilestradiol / Adesivo Transdérmico / Autorrelato Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans Idioma: En Revista: Contraception Ano de publicação: 2015 Tipo de documento: Article